LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・Ardelyx Inc

Ardelyx Inc

Closed

Sector Healthcare

5.62 2.18

Buy Sell

Overview

Share price change

24h

Current

Min

5.44

Max

5.75

Key metrics
By Trading Economics
Income	-33M -27M
Sales	12M 46M
EPS	-0.11
Profit margin	-57.619
Employees	267
EBITDA	-30M -22M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+84.34 upside

Dividends
By Dow Jones
Next Earnings	1 Aug 2024

Market Stats
By TradingEconomics
Market Cap	-21M 1.4B
Previous open	3.44
Previous close	5.62

News Sentiment

By Acuity

50%

123 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

5.425 / 5.76 Support & Resistance

Ardelyx Inc Chart

Related News

18 Oct 2023, 12:15 UTC

Major Market Movers

Ardelyx Shares Rally Premarket on FDA Approval of Xphozah

Peer Comparison

Price change

Ardelyx Inc Forecast

Price Target

By TipRanks

84.34% upside

12 Months Forecast

Average 10.36 USD 84.34%

High 12.5 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forArdelyx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Ardelyx Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.425 / 5.76Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

123 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.